Search

everythinglearnresearchcommunity

for

Search:↓

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

A 25-year-old shared progress pictures after using finasteride 1mg daily for 6 months and dutasteride 1.5mg daily for another 6 months, noting significant hair regrowth, especially in the temporal peaks, with no side effects. The user switched from finasteride to dutasteride for more effective treatment.

The conversation is about seeking information on GT20029 from Kintor Pharmaceutical as a potential hair loss cure and inquiring about experiences with CosmeaRNA.

A user's experience with the hair loss treatment Pyrilutamide KX-826, which has resulted in some side effects and shedding. The conversation also includes advice for baseline pictures and trying treatments for at least 6 months.

A user shared progress pictures of a hair transplant from Padra Clinic in Toronto, claiming 8000 hairs were transplanted for $4000 CAD. The post faced skepticism, with users questioning the results and clinic's credibility, while the user mentioned using zinc, biotin, and hair laser therapy for aftercare.

A user who was part of an ongoing trial for a prolactin blocker and had regrowth, but the progress photos were not shared due to negative reactions from other users. Treatments mentioned include HMI-115, Minoxidil, Finasteride, and RU58841.

A new hair loss treatment, KX-826, is being discussed as a stronger and safer alternative to RU58841 and finasteride. Opinions are mixed, with some users skeptical about its effectiveness and others considering it as part of their regimen.

A 28 year old using a hair loss prevention protocol to restore thinning hair, which includes finasteride, dutasteride, minoxidil, stemoxydine, alopecin, nizoral shampoo and microneedling; the user is now adding pyrilutamide solution to the regimen with the hope of improving their results. RU58841 was also ordered but not yet used.

The user increased their steroid dosage and noticed hair shedding, so they adjusted their regimen by reducing steroid doses and adding oral dutasteride. They are also experimenting with combining RU-58841 and KX-826/pyrilutamide in minoxidil to address hair loss.

The post discusses the completion of the HMI-115 Australian Phase 1 Trial for hair loss treatment. The user speculates about the potential early release of the trial results.

A user shared positive 6-month results from a hair transplant in Istanbul, receiving 4,450 grafts for the front and mid scalp and 850 for the crown. The procedure cost approximately €2,990.

PP405 shows promising results for hair growth, potentially outperforming finasteride without side effects like erectile dysfunction. Users discuss using treatments like minoxidil, pyrilutamide, nizoral, and alfatradiol while waiting for PP405's availability.

User tried various hair loss treatments with limited success. RU58841 was effective but caused side effects, now trying Eucapil and continuing Finasteride.

The conversation is about using finasteride and KX826 for hair loss treatment. The original poster is using 0.25 mg of finasteride every other day due to side effects at a higher dose.

RT1640, a combination of cyclosporin A, minoxidil, and RT175, is discussed as a potential treatment for hair regrowth and repigmentation. The unique formulation aims to enhance hair follicle growth and restore hair pigment without the negative side effects of immunosuppressants.

The conversation is about using KX-826 with minoxidil for hair regrowth. Users are sharing experiences and waiting for results.

A user is testing clascoterone (Winlevi) on their scalp for hair loss and has noticed a reduction in scalp sebum after one month. They are also using other unspecified treatments and plan to provide an update after the second month.

KX-826 Max combines KX-826, Kopyrrol, and Kopexil as a potential alternative to minoxidil and finasteride for hair loss, but users express skepticism about its effectiveness and high cost. Some users believe traditional treatments like minoxidil, finasteride, and others are more reliable.

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

The conversation is about a person's positive experience with hair loss treatment over seven years using finasteride, minoxidil, and a 1600 graft FUT hair transplant. They also mention the importance of taking vitamins and listening to advice from Kevin Mann.

A 28-year-old shared his successful hair transplant experience using 2800 grafts, oral minoxidil, and finasteride, resulting in a natural look. The procedure cost 1 lakh INR, and recovery took 7 days.

The conversation is about hair loss treatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.

A user developed an Android app to help track hair growth progress and is seeking testers, offering lifetime premium access in return. The user has been using treatments like Minoxidil, finasteride, and RU58841 since December 2024.

Dr. Bloxham's 9-month update on FUT scar revision with Verteporfin shows promising results. Excitement is high for FUE, which appears highly effective based on Dr. Barghouthi's findings.

PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.

A user discovered their hair regrowth progress pictures were used in a scam promoting a fake "elixir." The user clarified that their actual results came from using finasteride and minoxidil for three months.

A user experienced significant hair regrowth from Xeljanz after severe alopecia but can no longer afford it. They are seeking ways to obtain the medication despite its high cost and potential side effects.

Pyrilutamide (KX-826) is discussed as an anti-androgen treatment for hair loss, with mixed user experiences. Some users report no results, while others find it mildly effective.